Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD) a clinical-stage biopharmaceutical company focused on the development of CART-cell therapies,  today announced that the company will present updates on its ongoing Phase I clinical trials at the American Association for Cancer Research (AACR) Annual Meeting being held April 14–18, 2018, in Chicago. Poster presentations will feature updated data from Celyad’s THINK[1] trial, the new SHRINK[2] and LINK[3] trials in metastatic colorectal cancer, as well as data from a preclinical study showing that the addition of either the CD28 or 4-1BB co-stimulatory domains to CYAD-01 construct brings no benefit in terms of in vitro activity of the receptor.

Poster Presentation Details:

 

Poster Title: The THINK clinical trial: Preliminary evidence of clinical activity of NKG2D chimeric antigen receptor T cell therapy (CYAD-01) in acute   myeloid leukemia

Poster Number:  CT129

Session Title: Phase I Trials in Progress

Session Date & Time: Tuesday, April 17, 2018, 8:00 AM – 12:00 PM CDT

Location: Mc Cormick place south, Exhibit Hall A, Poster Section 42, Poster Board 12

 

Poster Title: The SHRINK clinical trial: A phase I study assessing the safety and clinical activity of multiple doses of an NKG2D-based CAR-T therapy, CYAD-01, administered concurrently with the neoadjuvant FOLFOX treatment in patients with potentially resectable liver metastases from colorectal cancer

Poster Number: CT123

Session Title: Phase I Trials in Progress

Session Date & Time: Tuesday, April 17, 2018, 8:00 AM – 12:00 PM CDT

Location: Mc Cormick place south, Exhibit Hall A, Poster Section 42, Poster Board 6

 

Poster Title:  The LINK clinical trial: A phase I study assessing the safety and clinical activity of multiple hepatic transarterial administrations of an NKG2D-based CAR-T therapy, CYAD-01, in patients with unresectable liver metastases from colorectal cancer

Poster Number: CT134

Session Title: Phase I Trials in Progress

Session Date & Time: Tuesday, April 17, 2018, 8:00 AM – 12:00 PM CDT

Location: Mc Cormick place south, Exhibit Hall A, Poster Section 42, Poster Board 17

 

Poster Title: NKG2D as a chimeric antigen receptor – DAP 10 provides optimal co-stimulation for NKG2D based CARs

Session Title: Adoptive Cell Therapy 3

Poster Number: 3583

Session Date & Time: Tuesday, April 17, 2018, 8:00 AM – 12:00 PM CDT

Location: Mc Cormick place south, Exhibit Hall A, Poster Section 24, Poster Board 21

 

 

***END***


[1] THINK – THerapeutic Immunotherapy with CAR-T NKG2D

[2] SHRINK – Standard CHemotherapy Regimen and Immunotherapy with CAR-T NKG2D

[3] LINK – Locoregional Immunotherapy with NKG2D

Download press release(s)

Press release

262.64 Ko

Communiqué de presse

263.68 Ko

About Celyad

Developing breakthrough pioneering therapies for life-threatening diseases.

Celyad is a biopharmaceutical company, specialized in cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis. Our scientific approach is inspired by the natural mechanisms that are used by the body to fight disease.

Read more about Celyad